Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials

The objective : to evalute effectiveness in clinical trials of the new kit reagents AmpliTest® MBT-Resist-I based on real-time PCR (RT-PCR) versus similar kits reagent registered Russia, identify genetic markers M. tuberculosis complex (MTB) resistance rifampicin (RIF) and isoniazid (INH) human biological samples MTB cultures. Subjects Methods . 200 DNA were studied, they had been obtained from specimens (sputum (N=100), bronchoalveolar lavage (N=50), biopsy (surgical material; N=50)) pulmonary patients containing at a concentration least 1 x 103 GE/ml, 100 Efficiency detecting mutations associated with RIF INH using was evaluated comparison HP Amplitube-MDR-RV (OOO Sintol, Russia). In case discordant results, target loci sequenced by Sanger. Results We observed complete agreement results consequently high efficiency rates (positive negative concordance - 100%, respectively) detection both INH, for two cultures, an additional mutation (I572L) rpoB gene detected which not confirmed Sanger sequencing. Conclusion Inhalers vary significantly patients' ability use them correctly. Asthma master correct inhalation technique better COPD patients. Liquid inhalers more difficult be used correctly, best multi-dose powder inhalers. patient's training healthcare professional is critical assure